Get the Stockscreener App
0.2635
2.41%
0.0062
Pre-market:
.24
-0.0235
-8.92%
Fibrobiologics Inc stock is traded at $0.2635, with a volume of 1.01M.
It is up +2.41% in the last 24 hours and up +0.08% over the past month.
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
See More
Previous Close:
$0.2573
Open:
$0.255
24h Volume:
1.01M
Relative Volume:
0.64
Market Cap:
$17.96M
Revenue:
-
Net Income/Loss:
$-18.65M
P/E Ratio:
-0.6002
EPS:
-0.439
Net Cash Flow:
$-16.66M
1W Performance:
+1.15%
1M Performance:
+0.08%
6M Performance:
-51.18%
1Y Performance:
-76.05%
1-Day Range:
$0.24
$0.2699
1-Week Range:
$0.24
$0.27
52-Week Range:
$0.2201
$1.53
Fibrobiologics Inc Stock (FBLG) Company Profile
Name
Fibrobiologics Inc
Sector
Industry
Phone
281-671-5150
Address
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
0.2635 | 17.96M | 0 | -18.65M | -16.66M | -0.439 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-24 | Initiated | H.C. Wainwright | Buy |
| Sep-24-24 | Initiated | Maxim Group | Buy |
Fibrobiologics Inc Stock (FBLG) Latest News
FibroBiologics announces 1-for-20 reverse stock split By Investing.com - Investing.com India
FibroBiologics stock tumbles on reverse stock split plan By Investing.com - Investing.com Australia
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement - Bitget
FibroBiologics announces 1-for-20 reverse stock split - Investing.com
FibroBiologics announces reverse stock split to regain compliance with Nasdaq's bid price requirement - marketscreener.com
To keep Nasdaq listing, FibroBiologics enacts 1-for-20 split - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
If You Invested $1,000 in Fibrobiologics (FBLG) - Stock Titan
FibroBiologics, Inc.: Fundamental Analysis and Financial Ratings | SG0 | US31573L1052 - marketscreener.com
FBLG SEC FilingsFibrobiologics 10-K, 10-Q, 8-K Forms - Stock Titan
FBLG Forecast, Price Target & Analyst Ratings | FIBROBIOLOGICS INC (NASDAQ:FBLG) - ChartMill
FibroBiologics, Inc. 2025 Executive Compensation and Leadership Overview - Minichart
FibroBiologics (NASDAQ: FBLG) adds 2025 governance, pay and ownership details - Stock Titan
FibroBiologics: CYWC628 Drives Buy Rating on Strong Preclinical Wound and Burn Data in Large Underserved Markets - TipRanks
D. Boral Capital Reiterates 'Buy' Rating for FibroBiologics - National Today
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology - Bitget
Gainers Report: Is FibroBiologics Inc benefiting from interest rate changesQuarterly Portfolio Summary & Safe Capital Growth Trade Ideas - baoquankhu1.vn
FibroBiologics sets new annual salary for CFO Jason D. Davis By Investing.com - Investing.com India
FibroBiologics Updates CFO Compensation to Support Leadership - TipRanks
FibroBiologics sets new annual salary for CFO Jason D. Davis - Investing.com
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers - Sahm
FibroBiologics completes site onboarding for diabetic ulcer trial By Investing.com - Investing.com Canada
Top Executive Makes Bold Move Into FibroBiologics Stock - TipRanks
FibroBiologics completes site onboarding for diabetic ulcer trial - Investing.com
FibroBiologics (FBLG) CSO Khoja buys $11k in stock - Investing.com
FibroBiologics (FBLG) CSO Khoja buys $11k in stock By Investing.com - Investing.com Australia
FibroBiologics Completes Site Onboarding for Phase 1/2 - GlobeNewswire
CEO Doubles Down on FibroBiologics With Bold Insider Stock Purchase - TipRanks
FBLG Earnings History & Surprises | EPS & Revenue Results | FIBROBIOLOGICS INC (NASDAQ:FBLG) - ChartMill
FibroBiologics CFO Buys 70,000 Shares - National Today
CFO’s Bold Insider Buy Sparks Fresh Buzz Around FibroBiologics Stock - TipRanks
Davis Jason, FibroBiologics CFO, buys $28973 in FBLG stock By Investing.com - Investing.com Australia
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Benzinga
Davis Jason, FibroBiologics CFO, buys $28973 in FBLG stock - Investing.com
FibroBiologics (FBLG) CFO purchases 70,000 shares in open-market trade - Stock Titan
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Newswire Canada
FibroBiologics receives patent for osteoporosis cell therapy By Investing.com - Investing.com Canada
Insider Makes Bold New Bet on FibroBiologics Stock - TipRanks
FBLG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
FibroBiologics Jumps 22% On New Osteoporosis Patent, Stock Up - Nasdaq
Garcia Ruben A, FibroBiologics general counsel, buys $13k in FBLG - Investing.com Australia
FibroBiologics receives patent for osteoporosis cell therapy - Investing.com
FibroBiologics, Inc. announces issuance of U.S. patent covering fibroblast cell therapy for the treatment of osteoporosis - marketscreener.com
Fibrobiologics, Inc. Announces Issuance Of U.S. Patent Covering Fibroblast Cell Therapy For The Treatment Of Osteoporosis - TradingView
FibroBiologics, Inc. Announces Issuance of U.S. Patent - GlobeNewswire
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis - Bitget
FBLG: Ready to Transition to Clinical-Stage Company - Smartkarma
Fibrobiologics Inc Stock (FBLG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):